May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Drug Pharmacokinetics in Rat Eye Tissues Following Topical Administration: Brimonidine
Author Affiliations & Notes
  • T.A. Birkebak
    Global Toxicology, Pharmacia Corp, Kalamazoo, MI, United States
  • S. Yamazaki
    Global Drug Metabolism, Pharmacia Corp, Kalamazoo, MI, United States
  • L.A. Adams
    Global Drug Metabolism, Pharmacia Corp, Kalamazoo, MI, United States
  • M. Shawer
    Global Pharmaceutical Sciences, Pharmacia Corp, Kalamazoo, MI, United States
  • S. Singh
    Global Pharmaceutical Sciences, Pharmacia Corp, Kalamazoo, MI, United States
  • L. Norris
    Global Pharmaceutical Sciences, Pharmacia Corp, Kalamazoo, MI, United States
  • B.W. Jones
    Global Pharmaceutical Sciences, Pharmacia Corp, Kalamazoo, MI, United States
  • T.L. VandeGiessen
    Global Pharmaceutical Sciences, Pharmacia Corp, Kalamazoo, MI, United States
  • J.J. Vrbanac
    Global Pharmaceutical Sciences, Pharmacia Corp, Kalamazoo, MI, United States
  • Footnotes
    Commercial Relationships  T.A. Birkebak, None; S. Yamazaki, None; L.A. Adams, None; M. Shawer, None; S. Singh, None; L. Norris, None; B.W. Jones, None; T.L. VandeGiessen, None; J.J. Vrbanac, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 1305. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      T.A. Birkebak, S. Yamazaki, L.A. Adams, M. Shawer, S. Singh, L. Norris, B.W. Jones, T.L. VandeGiessen, J.J. Vrbanac; Drug Pharmacokinetics in Rat Eye Tissues Following Topical Administration: Brimonidine . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1305.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: The rabbit is the species of choice in conducting preclinical ocular pharmacokinetic studies. Pharmacokinetic studies in the rabbit usually involve serial sacrifice of subjects with excision of ocular tissues, although more sophisticated techniques such as micro-dialysis have been employed. The rat is a primary preclinical species in models designed to study retinal degenerative diseases such as AMD and RD. However, the rat is not widely reported as a preclinical species for pharmacokinetic studies. This research examines the pharmacokinetics of a topically applied drug in the rat with excision of anterior and posterior tissues. We chose brimonidine as an initial test substance since this compound has been reported to distribute to the retina of rabbits and monkeys following topical ocular administration. Methods: Rats were dosed with 0.005 mL of a 0.15% [3-H]brimonidine tartrate solution buffered to pH 7.3. Animals were sacrificed at 10, 20, 30 and 60 minutes (n=1 per time point). Eye globes, retina, sclera, vitreous, lens and cornea were excised and combusted for radioanalysis. Results: Cmax was 6.28, 0.13, 0.98, 0.61, 1.39 µg*equivalents/g in the cornea, lens, vitreous, retina and sclera, respectively. Not surprisingly, concentrations of drug were highest in the cornea. In addition, the slower distribution of drug into the lens is not unexpected. The approximate amount of drug in retina was similar to what has been reported for Cmax in retina of rabbits following topical administration. Conclusions: The drug concentrations determined in ocular tissues showed tissue and time dependence and was not in disagreement with what would be expected based upon the literature. The excision of retina, sclera, vitreous, lens and cornea under a dissecting microscope from the rat was time consuming and it was concluded that excision of the retina alone would be sufficient for most studies examining the pharmacokinetics of drugs distributing to the retina following local ocular administration.

Keywords: drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×